{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:42:55Z","timestamp":1791650575465,"version":"4.3.4"},"reference-count":12,"publisher":"Japanese Society of Internal Medicine","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,10,1]]},"DOI":"10.2169\/internalmedicine.3115-23","type":"journal-article","created":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T22:17:08Z","timestamp":1709504228000},"page":"2703-2707","source":"Crossref","is-referenced-by-count":5,"title":["Cytokine Release Syndrome with Relative Adrenal Insufficiency Induced by Ipilimumab and Nivolumab Combination Therapy for Clear Cell Renal Cell Carcinoma"],"prefix":"10.2169","volume":"63","author":[{"given":"Kohei","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Shiotsu","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Japanese Red Cross Kyoto Daiichi Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misaki","family":"Sasakura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Goda","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Yuba","sequence":"additional","affiliation":[{"name":"Department of Infection Control, Japanese Red Cross Kyoto Daiichi Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieko","family":"Takumi","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Japanese Red Cross Kyoto Daiichi Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriya","family":"Hiraoka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med 383: 2255-2273, 2020.","DOI":"10.1056\/NEJMra2026131"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ceschi A, Noseda R, Palin K, Verhamme K. Immune checkpoint inhibitor-related cytokine release syndrome: analysis of WHO global pharmacovigilance database. Front Pharmacol 11: 557, 2020.","DOI":"10.3389\/fphar.2020.00557"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Brahmer JR, Lee JS, Ciuleanu TE, et al. Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in CheckMate 227. J Clin Oncol 41: 1200-1212, 2023.","DOI":"10.1200\/JCO.22.01503"},{"key":"4","unstructured":"4. National Cancer Center Japan. [The current status and important considerations for multicenter clinical trials of Nivolumab+Ipilimumab combination therapy in non-small cell lung cancer] [Internet]. 2023 Apr 28 [cited 2023 Oct 23]. Available from: https:\/\/www.ncc.go.jp\/jp\/information\/pr_release\/2023\/0428\/index.html (in Japanese)."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Tay SH, Toh MMX, Thian YL, et al. Cytokine release syndrome in cancer patients receiving immune checkpoint inhibitors: a case series of 25 patients and review of the literature. Front Immunol 13: 807050, 2022.","DOI":"10.3389\/fimmu.2022.807050"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Takai K, Nikkuni K, Shibuya H, et al. Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly. Rinsho Ketsueki 51: 320-325, 2010 (in Japanese).","DOI":"10.11406\/rinketsu.51.320"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kunimasa K, Inoue T, Matsueda K, et al. Cytokine release syndrome and immune-related pneumonitis associated with tumor progression in a pulmonary pleomorphic carcinoma treated with nivolumab plus ipilimumab treatment: a case report. JTO Clin Res Rep 3: 100272, 2021.","DOI":"10.1016\/j.jtocrr.2021.100272"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Urasaki T, Ono M, Mochizuki T, et al. Case report: a case of trimethoprim\/sulfamethoxazole-triggered hypotensive shock: cytokine release syndrome related to immune checkpoint inhibitors and drug-induced hypersensitivity syndrome. Front Oncol 11: 681997, 2021.","DOI":"10.3389\/fonc.2021.681997"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ohira J, Kawamoto M, Sugino Y, Kohara N. A case report of fulminant cytokine release syndrome complicated by dermatomyositis after the combination therapy with immune checkpoint inhibitors. Medicine (Baltimore) 99: e19741, 2020.","DOI":"10.1097\/MD.0000000000019741"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Sumi T, Koshino Y, Michimata H, et al. Cytokine release syndrome in a patient with non-small cell lung cancer on ipilimumab and nivolumab maintenance therapy after vaccination with the mRNA-1273 vaccine: a case report. Transl Lung Cancer Res 11: 1973-1976, 2022.","DOI":"10.21037\/tlcr-22-388"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Murata D, Azuma K, Tokisawa S, Tokito T, Hoshino T. A case of cytokine release syndrome accompanied with COVID-19 infection during treatment with immune checkpoint inhibitors for non-small cell lung cancer. Thorac Cancer 13: 2911-2914, 2022.","DOI":"10.1111\/1759-7714.14632"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Menakuru SR, Azeem Q, Priscu A, Khan I, Beirat A. Stage 4 cytokine release syndrome caused by the first dose of nivolumab and ipilimumab combination therapy in a patient with metastatic melanoma successfully treated with methylprednisolone, tocilizumab, and etanercept. Case Rep Oncol 15: 648-653, 2022.","DOI":"10.1159\/000525173"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/19\/63_3115-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T03:34:22Z","timestamp":1728099262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/19\/63_3115-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":12,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3115-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]},"article-number":"3115-23"}}